Publication date: Jun 19, 2024
Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalDatas report assesses how RMC-6236s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Melanoma.
| Concepts | Keywords |
|---|---|
| Cancer | Approval |
| Drugs | Cancer |
| Globaldatas | Clinical |
| Mutants | Company |
| Q61h | Drug |
| Indication | |
| Likelihood | |
| Medicines | |
| Melanoma | |
| Phase | |
| Ptsr | |
| Revolution | |
| Rmc | |
| Scores | |
| Specific |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| drug | DRUGBANK | Gold |
| pathway | KEGG | Ras signaling pathway |
| drug | DRUGBANK | Rasagiline |
| pathway | KEGG | Non-small cell lung cancer |
| disease | MESH | non-small cell lung cancer |
| disease | MESH | cancer |
| disease | MESH | adenocarcinoma |
| drug | DRUGBANK | Spinosad |
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |